Researchers at the CNIO (Spanish National Cancer Research Center) have discovered that one of the causes for the rare tumor pheochromocytoma-paraganglioma is the interruption of a very specific step in the production of some ...
May 9, 2023
0
10
(HealthDay) -- Extensive intratumor heterogeneity, seen in samples obtained from renal carcinomas, may lead to underestimation of the tumor genomics based on single tumor-biopsy samples, according to a study published in ...
Mar 8, 2012
0
0
The National Cancer Institute (INCan) has progressed from a rate of nine months of survival to 30 with personalized treatments for patients diagnosed with lung cancer in metastatic stage, i.e., when the disease has spread ...
Mar 10, 2014
0
1
A tumor can contain remarkable diversity, where even neighboring cells may differ greatly in terms of the mutations they contain. A device that can overcome this heterogeneity by enabling efficient analysis of both DNA and ...
Apr 30, 2019
0
1
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Apr 22, 2013
0
0
The investigational anticancer therapeutic AG-120, which targets mutant IDH1 protein, was well tolerated and showed signs of clinical activity in patients who had advanced solid tumors positive for mutant IDH1, according ...
Nov 9, 2015
0
9
A multidisciplinary team of investigators has developed a first-of-its-kind interactive 3D spatial approach that reveals new therapeutic targets and provides users with a comprehensive three-dimensional view of glioblastoma ...
Jan 19, 2024
0
3
A recent study in The FASEB Journal identifies a new mechanism of pancreatic tumors' resistance to chemotherapeutic treatment. The mechanism involves the loss of function of promyelocytic leukemia protein (PML), which operates ...
Sep 26, 2019
0
1
It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction ...
Apr 16, 2012
0
0
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...
Apr 8, 2013
0
0
